SCHEMBL10130719

SCHEMBL10130719

Cc1cc(N2CCN(C(C)C)CC2)ccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.53
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.53
PKM P14618 1/20 0.53
KHK P50053 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.44
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALOX12 P18054 1/20 0.44
GFER P55789 1/20 0.43
SUV39H2 Q9H5I1 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TP53 P04637 1/20 0.42
HTT P42858 2/20 0.41
MAPK1 P28482 1/20 0.41
ADRB1 P08588 2/20 0.41
CCR1 P32246 1/20 0.40
MT-CO2 P00403 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758199 0.88 MAPT (0.55) MAPTALDH1A1KDM4EPKMKHK
SCHEMBL11955710 0.86 MAPT (0.59) MAPTALDH1A1KDM4EPKMSMN1; SMN2
SCHEMBL18387991 0.84 MAPT (0.58) MAPTALDH1A1KDM4EPKMKHK
SCHEMBL3761235 0.83 CCR1 (0.54) MAPTALDH1A1KDM4EPKMSMN1; SMN2
SCHEMBL14922269 0.81 KMT2A (0.53) MAPTALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL16727172 0.80 MAPT (0.53) MAPTALDH1A1KDM4EPKMSMN1; SMN2
SCHEMBL22171241 0.80 GAA (0.62) MAPTALDH1A1KDM4EPKMKHK
SCHEMBL14426595 0.79 HPGD (0.54) MAPTALDH1A1KDM4EPKMSMN1; SMN2
SCHEMBL25556656 0.79 MAPT (0.51) MAPTALDH1A1KDM4EPKMKHK
SCHEMBL13898896 0.77 KDM4E (0.67) MAPTALDH1A1KDM4EPKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2024-01-18 US disclosed
US-8906913-B2 Azabicyclohexanes PANACEA BIOTEC LIMITED (IN) 2014-12-09 US disclosed
US-20120165320-A1 NOVEL AZABICYCLOHEXANES PANACEA BIOTEC LTD. (IN) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165320-A1 NOVEL AZABICYCLOHEXANES CYP3A43, UGT1A1, CYP3A4 MAPT 219/4885ALDH1A1 295/4885KDM4E 2799/4885
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS MAOA, DRD2, MAOB MAPT 191/4885ALDH1A1 1214/4885KDM4E 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.